Relay Therapeutics

  1. ​Relay uncloaks with $57M Series A round to join the next-gen cancer race
  2. FierceBiotech's 2017 Fierce 15
  3. Relay Therapeutics Secures $400 Million in Series C Financing

 

Nimbus Therapeutics

  1. ​​Discovering Nimbus
  2. ​Nimbus Discovery Secures $24 Million Series A Financing
  3. ​Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases
  4. Nimbus Delivers Its Apollo Mission: A $1.2B Gilead Partnership
  5. Nimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts

 

Schrodinger

  1. ​Schrödinger Announces Research Collaboration with Pfizer Inc
  2. Takeda, Schrödinger form multiprogram drug discovery pact
  3. Schrödinger, WuXi launch virtual drug discovery JV
  4. Schrödinger Closes $85 Million Financing to Advance Computational Platform and Expand Drug Discovery Pipeline
  5. ​Schrödinger Receives Clinical-Stage Milestone Payment from Sanofi Collaboration

 

EpiTherapeutics

  1. Gilead Sciences Acquires EpiTherapeutics


Constellation

  1. ​Constellation Pharmaceuticals and Genentech Enter Broad Epigenetics Drug Discovery Collaboration
  2. Constellation snags $100M 2 years after Genentech snub

 

Epizyme

  1. ​Epizyme Gets $90M in Epigenetics Partnership with Celgene
  2. ​Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies
  3. Epizyme, Genentech Expand Cancer Combo Collaboration
  4. Strategic Collaborations

 

Accent Therapeutics

  1. Accent Therapeutics Announces Company Launch with $40 Million Series A Financing for Novel, Precision Cancer Treatments Targeting RNA-Modifying Proteins